@article{APS6272,
author = {Xue-Sheng Feng and Xiu-Juan Zheng and Qiu-Sheng Si and Yun-Lu Lin and Yuan Chang and Pei-Fang Fan and Jian-Liang Yu and Shu-Ren Zhang and Xin-Yuan Liu},
title = {Antitumor effects of new-type recombinant interleukin-2},
journal = {Acta Pharmacologica Sinica},
volume = {13},
number = {5},
year = {2016},
keywords = {},
abstract = {Two new human recombinant interleukin-2 (rIL-2), 125-Ser-rIL-2, and 125-Ala-rIL-2, were generated by protein engineering technique. Both of them maintained the proliferation of natural killer (NK) cells, CTLL-2 cells and their long-term propagations. The mutated new rIL-2 also enhanced the bioactivity of NK cells and the cytotoxicity of tumor-infiltrating lymphocytes (TIL) against the target tumor cells. The above results were all compared with that of the native rIL-2 and a similarity between them was found, which indicates that new type rIL-2 could be used for adoptive immunotherapy of malignant diseases.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/6272}
}